A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia

International Journal of Medical Microbiology

Volumn 305, Issue 1, 2015, Pages 55-64

  van den Berg, Sanne ^a   Bonarius, Hendrik P J ^b   van Kessel, Kok P M ^c   Elsinga, Goffe S ^b   Kooi, Neeltje ^b   Westra, Hans ^b   Bosma, Tjibbe ^d   van der Kooi Pol, Magdalena M ^e   Koedijk, Danny G A M ^e   Groen, Herman ^b   van Dijl, Jan Maarten ^e   Buist, Girbe ^e   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IQ Therapeutics   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Lanthio Pharma   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bacteremia; Efficacy; Human monoclonal antibody; IsaA; Mouse; Staphylococcus aureus

Indexed keywords

BACTERIAL ANTIGEN; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY ID9; STAPHYLOCOCCAL ANTIGEN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BACTERIAL LOAD; BACTERIUM ISOLATE; CONTROLLED STUDY; DONOR SELECTION; DRUG DEVELOPMENT; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION PREVENTION; LEUKOCYTE ACTIVATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PROPHYLAXIS; PROTEIN EXPRESSION; RESPIRATORY BURST; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; SURVIVAL;

EID: 84940165789     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.11.002     Document Type: Article

References (38)

1. Albrecht M.T., Li H., Williamson E.D., LeButt C.S., Flick-Smith H.C., Quinn C.P., Westra H., Galloway D., Mateczun A., Goldman S., Groen H., Baillie L.W. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 2007, 75:5425-5433.
2. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J., Adcock K., Kaufman D., Puppala B., Riedel P., Hall B., White J., Cotton C.M. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006, 26:290-295.
3. Chambers H.F., DeLeo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 2009, 7:629-641.
4. Clarke S.R., Brummell K.J., Horsburgh M.J., McDowell P.W., Mohamad S.A., Stapleton M.R., Acevedo J., Read R.C., Day N.P., Peacock S.J., Mond J.J., Kokai-Kun J.F., Foster S.J. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 2006, 193:1098-1108.
5. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin. Infect. Dis. 2006, 42(Suppl. 2):S82-S89.
6. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 2005, 26:166-174.
7. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M., Jung E., Millard D., Schelonka R., Eyal F., Morris A., Kapik B., Roberson D., Kesler K., Patti J., Hetherington S. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151:260-265. 265.e1.
8. den Reijer P.M., Lemmens-den Toom N., Kant S., Snijders S.V., Boelens H., Tavakol M., Verkaik N.J., van Belkum A., Verbrugh H.A., van Wamel W.J. Characterization of the humoral immune response during Staphylococcus aureus bacteremia and global gene expression by Staphylococcus aureus in human blood. PLOS ONE 2013, 8:e53391.
9. Dreisbach A., Hempel K., Buist G., Hecker M., Becher D., van Dijl J.M. Profiling the surfacome of Staphylococcus aureus. Proteomics 2010, 10:3082-3096.
10. Dubrac S., Msadek T. Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J. Bacteriol. 2004, 186:1175-1181.
11. Falugi F., Kim H.K., Missiakas D.M., Schneewind O. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. MBio 2013, 4:e00575-e00613.
12. García-Lara J., Foster S.J. Anti-Staphylococcus aureus immunotherapy: current status and prospects. Curr. Opin. Pharmacol. 2009, 9:552-557.
13. Groen H., Westra H. Methods of Producing Stable B-lymphocytes 2010.
14. Kelly-Quintos C., Cavacini L.A., Posner M.R., Goldmann D., Pier G.B. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect. Immun. 2006, 74:2742-2750.
15. Kwakkenbos M.J., Diehl S.A., Yasuda E., Bakker A.Q., van Geelen C.M., Lukens M.V., van Bleek G.M., Widjojoatmodjo M.N., Bogers W.M., Mei H., Radbruch A., Scheeren F.A., Spits H., Beaumont T. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 2010, 16:123-128.
16. Lorenz U., Ohlsen K., Karch H., Hecker M., Thiede A., Hacker J. Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 2000, 29:145-153.
17. Lorenz U., Lorenz B., Schmitter T., Streker K., Erck C., Wehland J., Nickel J., Zimmermann B., Ohlsen K. Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy. Antimicrob. Agents Chemother. 2011, 55:165-173.
18. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520-532.
19. McDougal L.K., Steward C.D., Killgore G.E., Chaitram J.M., McAllister S.K., Tenover F.C. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 2003, 41:5113-5120.
20. Oesterreich B., Lorenz B., Schmitter T., Kontermann R., Zenn M., Zimmermann B., Haake M., Lorenz U., Ohlsen K. Characterization of the biological anti-staphylococcal functionality of hUK-66 IgG1, a humanized monoclonal antibody as substantial component for an immunotherapeutic approach. Hum. Vaccines Immunother. 2014, 10:926-937.
21. Ohlsen K., Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int. J. Med. Microbiol. 2010, 300:402-410.
22. Pancari G., Fan H.X., Smith S., Joshi A., Haimbach R., Clark D., Li Y.Z., Hua J., McKelvey T., Ou Y.S., Drummond J., Cope L., Montgomery D., McNeely T. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front. Cell. Infect. Microbiol. 2012, 2:36.
23. Rupp M.E., Holley H.P., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P., Veney N., Fowler V.G. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2007, 51:4249-4254.
24. Sakata N., Terakubo S., Mukai T. Subcellular location of the soluble lytic transglycosylase homologue in Staphylococcus aureus. Curr. Microbiol. 2005, 50:47-51.
25. Sibbald M.J., Ziebandt A.K., Engelmann S., Hecker M., de Jong A., Harmsen H.J., Raangs G.C., Stokroos I., Arends J.P., Dubois J.Y., van Dijl J.M. Mapping the pathways to staphylococcal pathogenesis by comparative secretomics. Microbiol. Mol. Biol. Rev. 2006, 70:755-788.
26. Sibbald M.J., Winter T., van der Kooi-Pol M.M., Buist G., Tsompanidou E., Bosma T., Schafer T., Ohlsen K., Hecker M., Antelmann H., Engelmann S., van Dijl J.M. Synthetic effects of secG and secY2 mutations on exoproteome biogenesis in Staphylococcus aureus. J. Bacteriol. 2010, 192:3788-3800.
27. Sibbald M.J., Yang X.M., Tsompanidou E., Qu D., Hecker M., Becher D., Buist G., van Dijl J.M. Partially overlapping substrate specificities of staphylococcal group A sortases. Proteomics 2012, 12:3049-3062.
28. Smith K., Garman L., Wrammert J., Zheng N.Y., Capra J.D., Ahmed R., Wilson P.C. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 2009, 4:372-384.
29. Stapleton M.R., Horsburgh M.J., Hayhurst E.J., Wright L., Jonsson I.M., Tarkowski A., Kokai-Kun J.F., Mond J.J., Foster S.J. Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus. J. Bacteriol. 2007, 189:7316-7325.
30. Stemerding A.M., Kohl J., Pandey M.K., Kuipers A., Leusen J.H., Boross P., Nederend M., Vidarsson G., Weersink A.Y., van de Winkel J.G., van Kessel K.P., van Strijp J.A. Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcgammaR antagonists that inhibit IgG-mediated effector functions. J. Immunol. 2013, 191:353-362.
31. Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 2008, 329:112-124.
32. Troelstra A., Giepmans B.N., van Kessel K.P., Lichenstein H.S., Verhoef J., van Strijp J.A. Dual effects of soluble CD14 on LPS priming of neutrophils. J. Leukoc. Biol. 1997, 61:173-178.
33. van den Berg S., Laman J.D., Boon L., ten Kate M.T., de Knegt G.J., Verdijk R.M., Verbrugh H.A., Nouwen J.L., Bakker-Woudenberg I.A. Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice. PLOS ONE 2013, 8:e59107.
34. van der Kooi-Pol M.M., de Vogel C.P., Westerhout-Pluister G.N., Veenstra-Kyuchukova Y.K., Duipmans J.C., Glasner C., Buist G., Elsinga G.S., Westra H., Bonarius H.P., Groen H., van Wamel W.J., Grundmann H., Jonkman M.F., van Dijl J.M. High anti-staphylococcal antibody titers in patients with epidermolysis bullosa relate to long-term colonization with alternating types of Staphylococcus aureus. J. Invest. Dermatol. 2013, 133:847-850.
35. Verkaik N.J., van Wamel W.J., van Belkum A. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 2011, 3:1063-1073.
36. Weems J.J., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P., Winston L., John J.F., Kubin C.J., Talwani R., Moore T., Patti J.M., Hetherington S., Texter M., Wenzel E., Kelley V.A., Fowler V.G. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006, 50:2751-2755.
37. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., Zheng N.Y., Mays I., Garman L., Helms C., James J., Air G.M., Capra J.D., Ahmed R., Wilson P.C. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
38. Ziebandt A.K., Kusch H., Degner M., Jaglitz S., Sibbald M.J., Arends J.P., Chlebowicz M.A., Albrecht D., Pantucek R., Doskar J., Ziebuhr W., Broker B.M., Hecker M., van Dijl J.M., Engelmann S. Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. Proteomics 2010, 10:1634-1644.